Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Thomas Sciascia, Chief Scientific Officer at Trevi Therapeutics, Inc. (NASDAQ:TRVI), executed a series of stock transactions on March 25, 2025. According to a recent SEC filing, Sciascia sold 2,631 shares of Trevi Therapeutics’ common stock at a price of $6.60 per share, amounting to a total sale value of $17,364. The transaction comes as TRVI shares have shown remarkable strength, with a 60% gain year-to-date and a market capitalization of $625 million. InvestingPro analysis indicates the stock is trading above its Fair Value, with analyst price targets ranging from $11 to $29.
In addition to the sale, Sciascia acquired 2,631 shares through stock options at an exercise price of $1.43 per share. These transactions were part of a routine filing and reflect changes in Sciascia’s holdings in the company. Following these transactions, Sciascia’s total holdings stand at 221,373 shares. The company maintains a strong financial position, with InvestingPro data showing more cash than debt and a healthy current ratio of 10.4, indicating robust liquidity.
The filing also noted that some of the shares were acquired through Trevi Therapeutics’ employee stock purchase plan, highlighting the ongoing participation of company executives in its equity programs. For deeper insights into insider trading patterns and comprehensive analysis, investors can access the full TRVI research report on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Trevi Therapeutics reported its fourth-quarter 2024 earnings, revealing a net loss of $11.4 million, which is an increase from the $7.8 million loss reported in the same period of the previous year. The company’s earnings per share (EPS) of -0.11 slightly outperformed the forecast of -0.12. Analysts from Raymond (NSE:RYMD) James maintained a Strong Buy rating on Trevi Therapeutics with a $29 price target, citing confidence in the potential of the company’s leading drug candidate, Haduvio. Stifel also maintained a Buy rating with a $15 price target, highlighting promising data from the Phase 2 Proof of Concept RIVER trial for Haduvio in Renal Cell Carcinoma.
Additionally, H.C. Wainwright reaffirmed a Buy rating and a $12.50 price target on Trevi Therapeutics, emphasizing the promising results from the Haduvio RIVER Phase 2a study for refractory chronic cough. The company is gearing up for the Phase 2b CORAL study outcomes in idiopathic pulmonary fibrosis-associated chronic cough, expected in the second quarter of 2025. Trevi’s focus remains on advancing Haduvio, with plans to present new data at the American Thoracic Society 2025 conference. The company’s cash reserves are projected to sustain operations into the second half of 2026, providing flexibility in its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.